<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05092009</url>
  </required_header>
  <id_info>
    <org_study_id>Lung Organoids</org_study_id>
    <nct_id>NCT05092009</nct_id>
  </id_info>
  <brief_title>Lung Cancer Organoids and Patient Derived Tumor Xenografts</brief_title>
  <acronym>Lung organoids</acronym>
  <official_title>Lung Cancer Organoids and Patient Derived Tumor Xenografts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extra tissue will be taken from patient during a procedure in standard of care. Also, through&#xD;
      an existing line, 10ml of extra blood will be drawn. From this material we will try to&#xD;
      establish matched normal and primary human lung cancer organoids.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung (tumor) material obtained from biopsies or surgical resection material that is not&#xD;
      needed by the pathologist for diagnosis (i.e. to stage the patient or to perform molecular&#xD;
      diagnosis) will be collected and used for the generation of matched normal and lung cancer&#xD;
      organoids and/or PDX.&#xD;
&#xD;
      Biopsy material: Patients with (suspected) lung cancer will undergo a bronchoscopy or&#xD;
      endobronchial ultrasound guided transbronchial needle aspiration (EBUS/EUS-TBNA) bronchoscopy&#xD;
      for the collection of a lung / lymph node biopsy. Biopsies are collected according to&#xD;
      standard of care procedures for i.e. the initial diagnosis and staging of lung cancer, and&#xD;
      molecular profiling of recurrent tumors. During the standard of care biopsy procedure, an&#xD;
      extra biopsy (lung and/or lymph node) will be collected and used for the generation of lung&#xD;
      (cancer) organoids:&#xD;
&#xD;
        -  Bronchoscopy: biopsy-derived lung (tumor) tissue from endobronchial tumors&#xD;
&#xD;
        -  EBUS/EUS-TBNA bronchoscopy: cytology-derived lung (tumor) cells from mediastinal lymph&#xD;
           nodes&#xD;
&#xD;
      A 10 ml blood sample will only be collected at the moment blood must be drawn according to&#xD;
      standard of care procedures or when the patient has received an intravenous drip. The patient&#xD;
      therefore does not require to undergo additional procedures.&#xD;
&#xD;
      Resection material: Patients who are selected to undergo surgical removal of a primary lung&#xD;
      cancer will be included. The (tumor) material that will be used to make organoids and PDX&#xD;
      will be derived from remaining healthy and tumor tissue that is not needed for the&#xD;
      pathologist to make a diagnosis, to stage the patient or to perform a molecular diagnosis.&#xD;
      The patient therefore does not require to undergo additional treatments or procedures. A 10&#xD;
      ml blood sample will be collected at the moment blood must be drawn pre-operatively according&#xD;
      to standard of care procedures or from the intravenous drip the patient will receive before&#xD;
      start surgery. The patient therefore does not require to undergo additional procedures.&#xD;
&#xD;
      Collection of clinical data: Clinical data will be collected from existing standard of care&#xD;
      data:&#xD;
&#xD;
        -  Histology&#xD;
&#xD;
        -  Date diagnosis lung cancer&#xD;
&#xD;
        -  TNM classification (eight edition)&#xD;
&#xD;
        -  If performed, molecular analysis data such as Epidermal Growth Factor Receptor (EGFR)&#xD;
           mutation, Anaplastic Lymphoma Kinase (ALK) translocation, Kirsten Rat Sarcoma (KRAS)&#xD;
           viral oncogene homolog mutation etc. (Type of test, results)&#xD;
&#xD;
        -  PD-L1 status if available. If available, type of test and PD-L1%&#xD;
&#xD;
        -  Type, dose, and date of treatment the patient received before and/or after the&#xD;
           collection tumor biopsy (chemotherapy, radiotherapy, tyrosine kinase inhibitors,&#xD;
           immunotherapy). If applicable, also the date and dose of all cycles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lung cancer organoids</measure>
    <time_frame>1 year</time_frame>
    <description>Establishing matched normal and primary human lung cancer organoids from patient-derived (tumor) tissue material by establishing long term culturing and bio-banking conditions for matched normal and primary lung cancer organoids from patient-derived lung (tumor) material. From these, we will In the established organoids we will:&#xD;
• the rate of proliferation and cell death (turnover) will be calculated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung cancer organoids</measure>
    <time_frame>1 year</time_frame>
    <description>Establishing matched normal and primary human lung cancer organoids from patient-derived (tumor) tissue material by establishing long term culturing and bio-banking conditions for matched normal and primary lung cancer organoids from patient-derived lung (tumor) material. From these, we will In the established organoids we will:&#xD;
• the size distribution of the organoids</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung cancer organoids</measure>
    <time_frame>1 year</time_frame>
    <description>Establishing matched normal and primary human lung cancer organoids from patient-derived (tumor) tissue material by establishing long term culturing and bio-banking conditions for matched normal and primary lung cancer organoids from patient-derived lung (tumor) material. From these, we will In the established organoids we will:&#xD;
• determine the frequency of primary, secondary and tertiary organoid formation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oncogenetic drivers</measure>
    <time_frame>1 year</time_frame>
    <description>To define oncogenic drivers in lung cancer organoids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor heterogeneity</measure>
    <time_frame>1 year</time_frame>
    <description>To investigate the stability of (epi-) genetic and phenotypic tumor heterogeneity of cultured organoids compared to a primary/secondary biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular biology</measure>
    <time_frame>1 year</time_frame>
    <description>To predict sensitivity and to get insight in the molecular biology of the response to immunotherapy, radiotherapy, cytotoxic and targeted agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response</measure>
    <time_frame>1 year</time_frame>
    <description>To compare treatment response in normal lung organoids and lung cancer organoids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Xenografts</measure>
    <time_frame>1 year</time_frame>
    <description>To establish and characterize patient-derived tumor xenografts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic approaches</measure>
    <time_frame>1 year</time_frame>
    <description>To test novel therapeutic approaches in lung cancer organoids and clinically relevant PDX models, including radiotherapy combined with hypoxia activated prodrugs and immunotherapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Developing biomarkers</measure>
    <time_frame>1 year</time_frame>
    <description>To develop biomarker(s) of tumor response to be able to select patients who will benefit from novel treatment strategies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysing blood</measure>
    <time_frame>1 year</time_frame>
    <description>To analyze (ct)DNA in organoid-derived culture supernatants and corresponding patient-derived blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysing blood</measure>
    <time_frame>1 year</time_frame>
    <description>To analyze metabolites in organoid-derived culture supernatants and corresponding patient-derived blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysing blood</measure>
    <time_frame>1 year</time_frame>
    <description>To analyze RNA in organoid-derived culture supernatants and corresponding patient-derived blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysing blood</measure>
    <time_frame>1 year</time_frame>
    <description>To analyze proteins in organoid-derived culture supernatants and corresponding patient-derived blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysing blood</measure>
    <time_frame>1 year</time_frame>
    <description>To analyze microvesicles secreted by lung cancer cells in organoid-derived culture supernatants and corresponding patient-derived blood samples</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>All patiens</arm_group_label>
    <description>There is only one arm in this trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tissue and blood</intervention_name>
    <description>Tissue and blood will be derived from patient during a standard of care procedure</description>
    <arm_group_label>All patiens</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and tumour tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with lung cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients selected to undergo primary surgical resection of a primary lung cancer.&#xD;
             All types of resection are eligible, e.g. wedge resection, segmental resection,&#xD;
             lobectomy, pneumonectomy.&#xD;
&#xD;
          -  All patients with (suspected) lung cancer that will undergo a bronchoscopy or&#xD;
             endobronchial ultrasound guided transbronchial needle aspiration (EBUS/EUS-TBNA)&#xD;
             bronchoscopy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        There are no exclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chantal Overhof, BEc.</last_name>
    <phone>+31 88 44 55 863</phone>
    <email>chantal.overhof@maastro.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ann Claessens</last_name>
    <phone>+31 88 44 55 863</phone>
    <email>ann.claessens@maastro.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zuyderland Medical Center</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Gerben Bootsma, MD, PhD</last_name>
      <phone>+31 884597810</phone>
      <email>g.bootsma@zuyderland.nl</email>
    </contact>
    <investigator>
      <last_name>Gerben Bootsma, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht Radiation Oncology (Maastro)</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 ET</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Chantal Overhof, BEc.</last_name>
      <phone>+31 884455863</phone>
      <email>chantal.overhof@maastro.nl</email>
    </contact>
    <contact_backup>
      <last_name>Ann Claessens</last_name>
      <phone>+31 884455863</phone>
      <email>ann.claessens@maastro.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Dirk De Ruysscher, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUMC+</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Roy Sprooten, MD</last_name>
      <phone>+31 43 3871318</phone>
      <email>r.sprooten@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Roy Sprooten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

